SCHEMBL24329836

SCHEMBL24329836

CN(C)Cc1ccc(-c2csc(NC(=O)c3ccn(C)n3)n2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.50
▸ KMT2A Q03164 6/20 0.50
▸ MEN1 O00255 5/20 0.50
▸ LMNA P02545 4/20 0.50
▸ ALDH1A1 P00352 3/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ MITF O75030 1/20 0.50
▸ NTSR1 P30989 1/20 0.50
▸ ROCK2 O75116 1/20 0.47
▸ ROCK1 Q13464 1/20 0.47
▸ HTT P42858 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ ABL1 P00519 1/20 0.45
▸ WNT3A P56704 1/20 0.44
▸ NPC1 O15118 2/20 0.44
▸ RAB9A P51151 2/20 0.44
▸ CASP3 P42574 1/20 0.44
▸ SENP8 Q96LD8 1/20 0.44
▸ SENP7 Q9BQF6 1/20 0.44
▸ SENP6 Q9GZR1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26658235 0.85 LMNA (0.59) MAPTKMT2AMEN1LMNAALDH1A1
SCHEMBL26884172 0.84 MEN1 (0.54) MAPTKMT2AMEN1LMNAALDH1A1
SCHEMBL26884180 0.84 KMT2A (0.61) MAPTKMT2AMEN1LMNAALDH1A1
SCHEMBL24330744 0.83 PARP1 (0.57) MAPTKMT2AMEN1LMNAALDH1A1
SCHEMBL24329679 0.82 MEN1 (0.62) MAPTKMT2AMEN1LMNAALDH1A1
SCHEMBL26884048 0.82 ROCK2 (0.57) MAPTKMT2AMEN1LMNAALDH1A1
SCHEMBL24329676 0.78 MAPT (0.53) MAPTKMT2AMEN1LMNAALDH1A1
SCHEMBL26884264 0.78 LMNA (0.51) MAPTKMT2AMEN1LMNAALDH1A1
SCHEMBL26884174 0.76 HDAC3 (0.53) MAPTKMT2AMEN1LMNAALDH1A1
SCHEMBL24329677 0.74 L3MBTL1 (0.67) MAPTKMT2AMEN1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 — — US disclosed
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 — — US disclosed
WO-2022082071-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF US THEREOF CARTHRONIX, INC. (US) 2022-04-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF STAT1, STAT3, STAT6 MAPT 4065/4885KMT2A 4379/4885MEN1 4814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback